If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Chair Succession Plan

3 Oct 2024 14:30

RNS Number : 8750G
Indivior PLC
03 October 2024
 

INDIVIOR PLC

CHAIR SUCCESSION PLAN

 

Richmond, VA, and Slough, UK, October 3, 2024 - Indivior PLC (Nasdaq/LSE: INDV) today announces that Graham Hetherington has informed the Board of his intention to retire as Chair and from the Board at the end of 2024 for personal reasons. Graham has been a member of the Board for five years, including four years as Chair of the Board.

The Nomination Committee, led by the Senior Independent Director, Juliet Thompson, has commenced a comprehensive search process to identify Graham's successor.

The Board would like to express its sincere thanks to Graham for his significant contribution to Indivior since joining the Board in 2019.

Graham Hetherington commented:

"It has been a privilege to serve as Chair of Indivior, working closely with an outstanding Board and highly dedicated management team who have an unwavering commitment to develop life-transforming treatments for patients suffering from substance use disorders, serious mental illness and overdose."

Key Contacts:

Jason Thompson

VP, Investor Relations

+1 804-402-7123 or jason.thompson@indivior.com

 

Tim Owens

Director, Investor Relations

+1 804-263-3978 or timothy.owens@indivior.com

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.

 

Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFSFFDDELSESS
Date   Source Headline
28th Feb 20259:43 amRNSDirector/PDMR Shareholding
28th Feb 20259:42 amRNSDirector/PDMR Shareholding
28th Feb 20257:00 amRNSHolding(s) in Company
27th Feb 20254:31 pmRNSDirector/PDMR Shareholding
27th Feb 20254:29 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSJoseph Ciaffoni Appointed Chief Executive Officer
25th Feb 20257:00 amRNSHolding(s) in Company
24th Feb 20257:00 amRNSFDA Approval of SUBLOCADE Label Changes
20th Feb 20257:00 amRNSFinal Results
12th Feb 20257:00 amRNSDelayed FDA Approval of SUBLOCADE Label Changes
4th Feb 20253:12 pmRNSNotice of Results
4th Feb 20257:00 amRNSCompletion of Share Repurchase Program
4th Feb 20257:00 amRNSTransaction in Own Shares
3rd Feb 20259:26 amRNSTotal Voting Rights
3rd Feb 20257:00 amRNSAppointment of Independent Non-Executive Director
28th Jan 20253:30 pmRNSDr. David Wheadon appointed Chair of the Board
28th Jan 20259:43 amRNSHolding(s) in Company
28th Jan 20257:00 amRNSTransaction in Own Shares
27th Jan 20259:08 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTransaction in Own Shares
16th Jan 20254:00 pmRNSReplacement Transaction in Own Shares
14th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20251:00 pmRNSIndivior Provides Historical Financials in US GAAP
7th Jan 20258:55 amRNSHolding(s) in Company
7th Jan 20257:00 amRNSTransaction in Own Shares
2nd Jan 20259:31 amRNSTotal Voting Rights
31st Dec 20249:53 amRNSHolding(s) in Company
31st Dec 20247:00 amRNSTransaction in Own Shares
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 202410:32 amRNSDirector/PDMR Shareholding
17th Dec 20247:00 amRNSIndivior Announces Changes to Board of Directors
17th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20249:44 amRNSTotal Voting Rights
26th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSIndivior to Participate in Upcoming Investor Event
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20248:48 amRNSHolding(s) in Company
15th Nov 20247:00 amRNSDirector Declaration
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20242:29 pmRNSHolding(s) in Company
8th Nov 20244:50 pmRNSBlock listing Interim Review
8th Nov 20247:00 amRNSIndivior Responds to Letter from Oaktree
5th Nov 20247:00 amRNSIndivior Completes Refinance of Secured Term Loan
5th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 202411:59 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares
24th Oct 20247:00 amRNS3rd Quarter Results
22nd Oct 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.